CN102994619A - NRAS gene mutation detection specificity primer and liquid chip thereof - Google Patents
NRAS gene mutation detection specificity primer and liquid chip thereof Download PDFInfo
- Publication number
- CN102994619A CN102994619A CN2011102697755A CN201110269775A CN102994619A CN 102994619 A CN102994619 A CN 102994619A CN 2011102697755 A CN2011102697755 A CN 2011102697755A CN 201110269775 A CN201110269775 A CN 201110269775A CN 102994619 A CN102994619 A CN 102994619A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- codon
- sites
- comprised
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an NRAS gene mutation detection specificity primer and a liquid chip thereof. The liquid chip mainly comprises: an ASPE primer composed of a 5'-terminal tag sequence and 3'-terminal specificity primer sequences focused on target gene mutation sites, wherein the specificity primer sequences comprise SEQ ID NO.18, SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 and/or SEQ ID NO.22 focused on a Codon12 site, SEQ ID NO.23, SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26 and/or SEQ ID NO.27 focused on a Codon13 site, SEQ ID NO.28 and SEQ ID NO.29 focused on a Codon18 site, and/or SEQ ID NO.30, SEQ ID NO.31, SEQ ID NO.32, SEQ ID NO.33 and/or SEQ ID NO.34 focused on a Codon61 site; a microsphere coated by an anti-tag sequence; and an amplimer. The consistency between the detection result of the detection liquid chip provided by the invention and the detection result of a sequencing method is high to 100%, and the wild-type and mutant parallel detection of a plurality of mutation sites is realized.
Description
Technical field
The invention belongs to biology field, relate to medical science and biotechnology, concrete a kind of NRAS detection in Gene Mutation Auele Specific Primer and the liquid-phase chip of relating to.
Background technology
The NRAS gene is the member of RAS Oncogene family, is positioned karyomit(e) No. 1, full length gene 85kb, and its cDNA is about 2.1kb, is that a coding contains 495 amino acid whose albumen, is called p21Ras.RAS albumen has ability and the GTP enzymic activity of GTP/GDP combination, and their normal function is to regulate albumen like the G protein, has the signal conduction from membrane-bound receptor to the adenylate cyclase process, participates in the normal regulation of cell cycle.Studies show that at present, the frequency that the N-ras transgenation occurs in the ras transgenation is the highest, and is the most common with the 12/13rd or 61 codon mutations, and the ras transgenation is in close relations relevant with the MDS prognosis.
The mutational site that the NRAS gene mutation detection liquid-phase chip that the present invention develops relates to is as shown in the table:
At present, the method that determination and analysis is carried out in the NRAS transgenation seldom mainly contains direct sequencing and PCR-RFLP analytical method, and wherein the most frequently used method has the PCR-RFLP analytical method.The PCR-RFLP method is based on the change of the restriction enzyme enzyme recognition site that transgenation causes, as losing or produce novel site in the site, by a certain specific fragment of pcr amplification, use again the digestion with restriction enzyme amplified production, the size of electrophoresis observation fragment, this method can directly be judged genotype for detection of the transgenation that restriction enzyme site changes, but this method can not be used for not producing the detection in Gene Mutation of new restriction enzyme site.Again, above these methods all exist the limitation that detects flux, can only detect a kind of mutation type at every turn, can not satisfy the needs of practical application.
Summary of the invention
One of purpose of the present invention provides the NRAS gene mutation detection liquid-phase chip; this liquid-phase chip can be used for individual event or detects side by side the normal genotype of NRAS gene C odon 12 and four kinds of mutant: G12S, G12C, G12D, G12A; the normal genotype of Codon13 and four kinds of mutant: G13R, G13D, G13A, G13V; the normal genotype of Codon18 and a kind of mutant: A18T, and the normal genotype of Codon 61 and four kinds of mutant: Q61K, Q61L, Q61P, Q61R.
The technical scheme that realizes above-mentioned purpose is as follows:
A kind of NRAS gene mutation detection liquid-phase chip includes:
(A). the wild-type that designs respectively for different mutational sites and the ASPE primer of mutant: every kind of ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene mutational site, and described specific primer sequence is: for the SEQ ID NO.18 in Codon 12 sites and among SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 and the SEQ IDNO.22 more than one; For the SEQ ID NO.23 in Codon 13 sites and among SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26 and the SEQ ID NO.27 more than one; SEQ ID NO.28 and SEQ IDNO.29 for the Codon18 site; And/or for the SEQ ID NO.30 in Codon 61 sites and among SEQ ID NO.31, SEQ ID NO.32, SEQ IDNO.33 and the SEQ ID NO.34 more than one; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.17;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.35～SEQ ID NO.51, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding mutational site.
Preferably, described amplimer is SEQ ID NO.52 and the SEQ ID NO.53 for Codon 12, Codon 13, Codon18 site; And/or for SEQ ID NO.54 and the SEQ ID NO.55 in Codon 61 sites.
Preferably, described ASPE primer is: the sequence that forms for the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.18 in Codon 12 sites and the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.19, by SEQ ID NO.3 and SEQ ID NO.20, the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.21 and/or the sequence that is comprised of SEQ ID NO.5 and SEQ ID NO.22; The sequence that forms for the sequence that is formed by SEQ ID NO.6 and SEQ ID NO.23 in Codon 13 sites and the sequence that is formed by SEQ ID NO.7 and SEQ ID NO.24, by SEQ ID NO.8 and SEQ ID NO.25, the sequence that is formed by SEQ ID NO.9 and SEQ ID NO.26 and/or the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.27; The sequence that is comprised of SEQ ID NO.11 and SEQ ID NO.28 for the Codon18 site reaches the sequence that is comprised of SEQ ID NO.12 and SEQ IDNO.29; And/or the sequence that forms for the sequence that is formed by SEQ ID NO.13 and SEQ ID NO.30 in Codon 61 sites and the sequence that is formed by SEQ ID NO.14 and SEQ ID NO.31, by SEQ ID NO.15 and SEQ ID NO.32, the sequence that is formed by SEQ ID NO.16 and SEQ ID NO.33 and/or the sequence that is formed by SEQ ID NO.17 and SEQ ID NO.34.
Another object of the present invention provides the Auele Specific Primer for the NRAS detection in Gene Mutation.
The technical scheme that realizes above-mentioned purpose is as follows:
Be used for the Auele Specific Primer of NRAS detection in Gene Mutation, it is: for the SEQ ID NO.18 in Codon 12 sites and among SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 and the SEQ ID NO.22 more than one; For the SEQ ID NO.23 in Codon 13 sites and among SEQ ID NO.24, SEQ ID NO.25, SEQ ID NO.26 and the SEQ ID NO.27 more than one; For the SEQ ID NO.28 in Codon18 site and among the SEQ ID NO.29 more than one; And/or for the SEQ ID NO.30 in Codon 61 sites and among SEQ ID NO.31, SEQ ID NO.32, SEQ ID NO.33 and the SEQ IDNO.34 more than one.
Major advantage of the present invention is:
1. the identical rate of detection method provided by the present invention and sequencing is up to 100%.And detect the needed time well below sequencing technologies commonly used, realistic especially application needs.Prepared NRAS gene mutation detection liquid-phase chip has extraordinary signal-noise ratio, and basically there is not cross reaction between designed probe and the anti-tag sequence, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection in a plurality of mutational sites.
2. the present invention has chosen optimum combination by the design experiences of contriver's long-term accumulation and a large amount of experimental implementation from numerous Auele Specific Primers.The ASPE primer specificity primer of the present invention's design can sensitive be identified the mutational site of target detect specifically, accurately distinguishes the genotype of various types; In same reaction system, between the different Auele Specific Primers, basically do not have cross reaction between the pcr amplification product of Auele Specific Primer and non-target detect, detection specificity is good, and cross reacting rate is lower than 3%; Except detecting Single locus sudden change situation, also the sudden change situation in a plurality of mutational sites of simultaneously parallel detection detects effect consistent.
3. detection method step of the present invention is simple, the amplification that can finish by a step PCR 2 objective sequences is detected in 13 kinds of mutational sites, many uncertain factors of existing in the complex operations processes such as repeated multiple times PCR have been avoided, thereby can greatly improve Detection accuracy, embodied accurate while qualitative and quantitative analysis feature.
4. not only to have overcome traditional solid phase chip susceptibility not high in the present invention, and the defective that the repeatability of detected result is poor is improved existing liquid-phase chip technology simultaneously, so that prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value that detects improves greatly, thereby so that the sensitivity that detects is further enhanced, signal to noise ratio strengthens, and detected result more accurately and reliably.
Embodiment
Embodiment 1 NRAS gene mutation detection liquid-phase chip mainly includes:
One, ASPE primer
For the normal genotype of NRAS gene C odon 12 and four kinds of mutant: G12S, G12C, G12D, G12A; the normal genotype of Codon 13 and four kinds of mutant: G13R, G13D, G13A, G13V; the normal genotype of Codon18 and a kind of mutant: A18T; and the normal genotype of Codon 61 and four kinds of mutant: Q61K, Q61L, Q61P, Q61R, design respectively specific primer sequence.The ASPE primer is comprised of " tag sequence+specific primer sequence ".The ASPE primer sequence is as shown in the table:
The ASPE primer sequence of table 1 NRAS gene (tag sequence+specific primer sequence)
Every the ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence for anti-tag sequence on the corresponding microballoon, and 3 ' end is mutant or the special primer fragment (as shown in Table 1 above) of wild-type.All ASPE primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Two, the coated microballoon of anti-tag sequence
According to designed ASPE Auele Specific Primer fragment, select the tag sequence, reduce to greatest extent between the anti-tag sequence of each microballoon and secondary structure that tag and ASPE Auele Specific Primer fragment may form, corresponding anti-tag sequence is as shown in table 2 on 17 kinds of microballoons numberings of selection and the microballoon:
Corresponding anti-tag sequence on table 2 microballoon numbering and the microballoon
17 kinds of microballoons selecting are coated in the anti-tag sequence on the microballoon available from U.S. Luminex company.Be connected with the spacerarm sequence of 5-10 T between anti-tag sequence and the microballoon, namely add the spacerarm sequence of the preceding paragraph 5-10 T before each anti-tag sequence, the anti-tag sequence is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.With synthetic anti-tag sequence sterilization ddH
2O is made into the stock solution of 100nmol/ml.Described spacerarm is for being used for anti-tag and microsphere surface is spaced apart or anti-tag is placed the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (DT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are such as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the process that microballoon is coated with is as follows:
Get respectively 5 * 10
6The carboxylated microballoon of individual above-mentioned numbering (available from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (available from the Pierce Chemical company) working fluid of preparation 10ng/ml.The EDC working fluid that adds 2.5ul in the microballoon suspension, constant-temperature incubation 30 minutes adds the EDC working fluid of 2.5ul again, and constant-temperature incubation is 30 minutes again.After reaction finished, the Tween-20 washing with 0.02% was once washed once with 0.1% SDS liquid again.The microballoon that is coated with the anti-tag sequence after the washing is resuspended in the Tris-EDTA solution [10mmol/L Tris (pH8.0)] of 100ul, among the 1mmol/LEDTA, 2-8 ℃ keeps in Dark Place.
Three, amplify the primer of the target sequence that contains the mutational site
For Codon12, Codon13, Codon18 and the Codon61 of NRAS gene, design of amplification primers amplifies 2 target sequences that contain the mutational site to (seeing Table 3), and wherein Codon12, Codon13 and Codon18 are positioned at the same amplified production.
Table 3 amplifies the primer of the target sequence with mutational site
All primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Embodiment 2 uses embodiment 1 described NRAS gene mutation detection liquid-phase chip to the detection of sample
The prescription of described various solution is as follows:
MES damping fluid (pH5.0) prescription (250ml) of 50mM:
2 * Tm hybridization buffer
Be stored in 4 ℃ after the filtration.The ExoSAP-IT test kit is available from U.S. USB company.
Biotin labeled dCTP is available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
One, the DNA extraction of sample:
With reference to " molecular cloning " methods involving about DNA extraction, obtain DNA to be detected.
Two, the pcr amplification of testing sample
Design 2 pairs of primers, one step of multiplex PCR amplifies contains respectively the common genotypic 2 objective sequences of NRAS gene C odon12, Codon13, Codon18 and Codon61, wherein, Codon12, Codon13 and Codon18 are positioned at the same amplified production, the product size is respectively 189bp and 364bp, and primer sequence (SEQ ID NO.52-55) is seen shown in the above-mentioned table 3.
At first prepare the multiple PCR primer working fluid: respectively get respectively the primer stock solution 100ul of SEQ ID NO.52-55 in the 1.5ml Eppendorf tube, mix and be the multiple PCR primer working fluid.The multi-PRC reaction system is as follows:
The pcr amplification program is: 95 ℃ of 3min; 94 ℃ of 30s, 56 ℃ of 30s, 72 ℃ of 40s, 30 circulations; 72 ℃ of 10min; 4 ℃ save backup.
Three, the enzyme of PCR product is cut processing
1. get the reacted product of 7.5ul PCR, add 1ul 10 * SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;
2.37 ℃ hatch 15min, hatch 15min for 80 ℃, the enzyme that deactivation is unnecessary.The product that enzyme is cut after the processing is directly used in follow-up ASPE primer extension reaction.
Four, site-specific primer extension reaction (ASPE)
Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make a plurality of biotin labeling on the reacted product band.
At first prepare the ASPE primer working fluid that mixes: get respectively the corresponding wild-type of gene to be detected and mutant ASPE primer stock solution 10ul in the 1.5ml Eppendorf tube, add 10mmol/L Tris Buffer and mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:
Response procedures is: 96 ℃ of 2min; 94 ℃ of 30s, 54 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 4 ℃ save backup.
Five, hybridization
According to the design the ASPE primer, the corresponding 17 kinds of coated microballoons of every group selection (as described in Example 1), every kind of microballoon concentration is 2.5 * 10
5Individual/ml;
2. get respectively the microballoon of every kind of numbering of 1ul in the Eppendorf tube of 1.5ml;
3. microballoon is in 〉=centrifugal the 1-2min of 10000g;
4. supernatant discarded, microballoon is resuspended in 2 * Tm hybridization buffer of 100ul, the vortex mixing;
5. get the above-mentioned microballoon suspension of 25ul in the corresponding hole of 96 hole filter plates, control wells adds the ddH of 25ul
2O;
6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH
2O complements to 50ul;
7. encase 96 orifice plates with lucifuge with masking foil, 95 ℃ of 60s, 37 ℃ of 15min are hatched hybridization;
8. the microballoon after the hybridization is in 〉=centrifugal the 2-5min of 3000g;
9. remove supernatant, microballoon is resuspended in 1 * Tm hybridization buffer of 75ul;
10. microballoon is in 〉=centrifugal the 2-5min of 3000g;
11. microballoon is resuspended in 1 * Tm hybridization buffer of 75ul, adding 15ul concentration is the SA-PE (SA-PE) of 10ug/ml;
12.37 ℃ hatch 15min, on the Luminex instrument, detect.
Six, the result detects and data analysis
The reaction after product detects by Luminex serial analysis instrument.Greater than 100 as the cut-off value, the MFI value that detects when mutant is judged that there is this mutation type in this sample, otherwise is judged that this sample is corresponding wild-type greater than 100 the time take mutant fluorescent value (MFI).
Use present method to detect the NRAS transgenation of great amount of samples, compare with the liquid-phase chip result with the sequencing detection, calculate the identical rate of method detected result provided by the present invention.Present method detects 20 increments NRAS genotype detection result and the sequencing result rate of coincideing originally and reaches 100%.As seen NRAS gene mutation detection liquid-phase chip provided by the present invention can detect the mutation type of NRAS gene exactly, and the result is reliable and stable.
One of table 4 pattern detection result (MFI)
Table 5 pattern detection result's (MFI) two
Table 6 sample NRAS gene mutation type analytical results
| Catalogue number(Cat.No.) | The liquid-phase chip detected result | Sequencing result |
| 1 | Wild-type | Wild-type |
| 2 | G12C | G12C |
| 3 | Wild-type | Wild-type |
| 4 | Wild-type | Wild-type |
| 5 | Wild-type | Wild-type |
| 6 | Wild-type | Wild-type |
| 7 | Wild-type | Wild-type |
| 8 | Wild-type | Wild-type |
| 9 | Q61L | Q61L |
| 10 | Wild-type | Wild-type |
| 11 | Wild-type | Wild-type |
| 12 | Wild-type | Wild-type |
| 13 | Wild-type | Wild-type |
| 14 | G13D | G13D |
| 15 | Wild-type | Wild-type |
| 16 | Wild-type | Wild-type |
| 17 | G13A | G13A |
| 18 | Wild-type | Wild-type |
| 19 | Wild-type | Wild-type |
| 20 | Wild-type | Wild-type |
The liquid-phase chip of the ASPE primer that embodiment 3 is different is to the detection of NRAS gene mutation site
One, the design (selection of Tag sequence and Anti-Tag sequence) of liquid-phase chip preparation
Detect liquid-phase chip as example take NRAS gene G12S and G13R site mutation, respectively for the wild-type of G12S and G13R and the specific primer sequence of mutant design ASPE primer 3 ' end, the Tag sequence of ASPE primer 5 ' end then is selected from SEQ IDNO.1-SEQ ID NO.17, accordingly, the anti-tag sequence with corresponding tag sequence complementary pairing that is coated on the microballoon is selected from SEQID NO.35-SEQ ID NO.51.Specific design is shown in following table (table 7).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
The design of table 7 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 21-40 is detected, detected result is as follows:
Table 8 pattern detection result and gene mutation analysis
Table 9 pattern detection result and gene mutation analysis
By the present embodiment as seen, when the ASPE primer was selected among the embodiment 1 collocation of tag sequence and specific primer sequence, effect better (signal to noise ratio is better) was referring to the present embodiment test group 1 and test group 4.Other different tag sequences and specific primer sequence collocation, with coming to the same thing of embodiment 2 and the present embodiment, concrete data are omitted.
Other is for the liquid-phase chip in different mutational sites, the ASPE primer uses different Tag sequences, and its result is still reliable and stable, and the ASPE primer is selected when the tag sequence is arranged in pairs or groups with specific primer sequence among the embodiment 1, effect better (signal to noise ratio is better), concrete data are omitted.
The selection of embodiment 4 NRAS detection in Gene Mutation specific primer sequences
One, the design (selection of wild-type and mutant specific primer sequence) of liquid-phase chip preparation
Detect liquid-phase chip as example take the mutational site of NRAS gene G12C and Q61K, take the forward or backwards complementary sequence of this place, mutational site target sequence as template, respectively for the wild-type of G12C and Q61K and the specific primer sequence of mutant design ASPE primer 3 ' end, comprise preferred specific primer sequence and 2 alternative specific primer sequences in the embodiment of the invention 1, as shown in table 10.Wherein,
Interior base is the mutational site.
Table 10 specific primer sequence
Detect liquid-phase chip as example take the mutational site of NRAS gene G12C and Q61K, select different specific primer sequences for G12C and Q61K, the Tag sequence of ASPE primer 5 ' end then is fixed as the best effect sequence among the embodiment 1, and select with it corresponding anti-tag sequence, specific design is shown in following table (table 11).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
Two of the design of table 11 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 41-60 is detected, detected result is as follows:
Table 12 pattern detection result and gene mutation analysis
Table 13 pattern detection result and gene mutation analysis
By the present embodiment as seen, when the ASPE primer was selected among the embodiment 1 collocation of specific primer sequence and tag sequence, effect better (signal to noise ratio is better) was referring to the present embodiment test group 7 and test group 10.Other derives from different specific primer sequences and the collocation of tag sequence of the forward or backwards complementary sequence of place, target detect site sequence, with coming to the same thing of embodiment 2 and the present embodiment, namely still be that the specific primer sequence described in the embodiment 1 is better from different tag sequence arranging effects, concrete data are omitted.Other is for multiple specific primer sequence and the collocation of tag sequence in the multiple specific primer sequence in identical mutation site or different mutational site, with coming to the same thing of embodiment 2 and the present embodiment, it is embodiment 1 selected Auele Specific Primer, has better signal to noise ratio, detect effect also better, concrete data are omitted.
More than be for the specifying of possible embodiments of the present invention, but this embodiment limits claim of the present invention, allly do not break away from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the claim of the present invention.
Claims (6)
1. a NRAS gene mutation detection liquid-phase chip is characterized in that, includes:
(A). the wild-type that designs respectively for the different mutational sites of NRAS gene and the ASPE primer of mutant: every kind of ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene mutational site, and described specific primer sequence is: for the SEQ ID NO.18 in Codon 12 sites and among SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 and the SEQ ID NO.22 more than one; For the SEQ ID NO.23 in Codon 13 sites and among SEQ ID NO.24, SEQID NO.25, SEQ ID NO.26 and the SEQ ID NO.27 more than one; SEQ ID NO.28 and SEQ IDNO.29 for the Codon18 site; And/or for the SEQ IDNO.30 in Codon 61 sites and among SEQ IDNO.31, SEQ IDNO.32, SEQ ID NO.33 and the SEQ ID NO.34 more than one; Described tag sequence is selected from SEQ ID NO.1～SEQ IDNO.17;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.35～SEQ ID NO.51, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding mutational site.
2. NRAS gene mutation detection liquid-phase chip according to claim 1 is characterized in that, described amplimer is: for SEQ ID NO.52 and the SEQ ID NO.53 in Codon 12, Codon 13, Codon 18 sites; And/or for SEQ ID NO.54 and the SEQ ID NO.55 in Codon 61 sites.
3. NRAS gene mutation detection liquid-phase chip according to claim 1, it is characterized in that, described ASPE primer is: the sequence that forms for the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.18 in Codon 12 sites and the sequence that is comprised of SEQ ID NO.2 and SEQ IDNO.19, by SEQ ID NO.3 and SEQ ID NO.20, the sequence that is comprised of SEQ ID NO.4 and SEQ IDNO.21 and/or the sequence that is comprised of SEQ ID NO.5 and SEQ ID NO.22; The sequence that forms for the sequence that is formed by SEQ ID NO.6 and SEQ ID NO.23 in Codon 13 sites and the sequence that is formed by SEQ ID NO.7 and SEQ ID NO.24, by SEQ ID NO.8 and SEQ ID NO.25, the sequence that is formed by SEQ ID NO.9 and SEQ ID NO.26 and/or the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.27; The sequence that is comprised of SEQ ID NO.11 and SEQID NO.28 for the Codon18 site reaches the sequence that is comprised of SEQ ID NO.12 and SEQ ID NO.29; And/or the sequence that forms for the sequence that is formed by SEQ ID NO.13 and SEQ ID NO.30 in Codon 61 sites and the sequence that is formed by SEQ ID NO.14 and SEQ ID NO.31, by SEQ ID NO.15 and SEQ ID NO.32, the sequence that is formed by SEQ ID NO.16 and SEQ ID NO.33 and/or the sequence that is formed by SEQ ID NO.17 and SEQ ID NO.34.
4. NRAS gene mutation detection liquid-phase chip according to claim 1 is characterized in that:
(A) described ASPE primer is: the sequence that forms for the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.18 in Codon 12 sites and the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.19, by SEQ ID NO.3 and SEQ ID NO.20, the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.21 and the sequence that is comprised of SEQ ID NO.5 and SEQ ID NO.22; The sequence that forms for the sequence that is formed by SEQ ID NO.6 and SEQ ID NO.23 in Codon 13 sites and the sequence that is formed by SEQ ID NO.7 and SEQ IDNO.24, by SEQ ID NO.8 and SEQ ID NO.25, the sequence that is formed by SEQ ID NO.9 and SEQ IDNO.26 and the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.27; The sequence that is comprised of SEQ ID NO.11 and SEQ ID NO.28 for the Codon18 site reaches the sequence that is comprised of SEQ ID NO.12 and SEQ ID NO.29; The sequence that forms with the sequence that forms for the sequence that is formed by SEQ ID NO.13 and SEQ ID NO.30 in Codon 61 sites and the sequence that is formed by SEQ ID NO.14 and SEQ ID NO.31, by SEQ ID NO.15 and SEQ ID NO.32, by SEQ ID NO.16 and SEQ ID NO.33 and the sequence that is formed by SEQ ID NO.17 and SEQ ID NO.34;
(B) anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.35～SEQ ID NO.51, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C) described amplimer is: for SEQ ID NO.52 and the SEQ ID NO.53 in Codon 12, Codon 13, Codon18 site; With SEQ ID NO.54 and the SEQ ID NO.55 for Codon 61 sites.
5. each described NRAS gene mutation detection liquid-phase chip is characterized in that according to claim 1-4, and described spacerarm is 5-10 T.
6. the Auele Specific Primer that is used for NRAS detection in Gene Mutation liquid, it is characterized in that, described specific primer sequence is among the SEQ ID NO.18 in Codon 12 sites and SEQ ID NO.19, SEQ ID NO.20, SEQ ID NO.21 and the SEQ ID NO.22 more than one; For the SEQ ID NO.23 in Codon 13 sites and among SEQ ID NO.24, SEQ ID NO.25, SEQ IDNO.26 and the SEQ ID NO.27 more than one; SEQ ID NO.28 and SEQ ID NO.29 for Codon 18 sites; And/or for the SEQ ID NO.30 in Codon 61 sites and among SEQ ID NO.31, SEQ ID NO.32, SEQ ID NO.33 and the SEQ ID NO.34 more than one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110269775.5A CN102994619B (en) | 2011-09-13 | 2011-09-13 | NRAS gene mutation detection specificity primer and liquid chip thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110269775.5A CN102994619B (en) | 2011-09-13 | 2011-09-13 | NRAS gene mutation detection specificity primer and liquid chip thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102994619A true CN102994619A (en) | 2013-03-27 |
| CN102994619B CN102994619B (en) | 2014-12-10 |
Family
ID=47923725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110269775.5A Active CN102994619B (en) | 2011-09-13 | 2011-09-13 | NRAS gene mutation detection specificity primer and liquid chip thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102994619B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023433A1 (en) * | 2013-08-14 | 2015-02-19 | Primeradx, Inc. | Compositions and methods for multiplex analysis of nras and braf nucleic acids |
| CN104372103A (en) * | 2014-12-05 | 2015-02-25 | 武汉友芝友医疗科技有限公司 | NRAS gene mutation detection kit |
| CN105986018A (en) * | 2015-02-06 | 2016-10-05 | 上海赛安生物医药科技有限公司 | NRAS gene mutation detection system and kit thereof |
| KR20170009605A (en) * | 2015-07-17 | 2017-01-25 | 서울대학교산학협력단 | Composition for detecting mutations of NRAS gene and kit comprising the same |
| TWI586810B (en) * | 2016-07-18 | 2017-06-11 | 豐技生物科技股份有限公司 | Method for detecting mutation sites of nras gene |
| EP3150719A4 (en) * | 2014-05-30 | 2018-01-03 | Jiaxing ACCBDiagnostics Ltd. | Nras gene mutation detection kit |
| CN107937525A (en) * | 2017-12-08 | 2018-04-20 | 益善生物技术股份有限公司 | NRAS mutation detection kits and extension primer based on Luminex |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
-
2011
- 2011-09-13 CN CN201110269775.5A patent/CN102994619B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
Non-Patent Citations (1)
| Title |
|---|
| MINORU TADA ET AL.: "High Incidence of ras Gene Mutation in lntrahepatic Cholangiocarcinoma", 《CANCER》, vol. 69, no. 5, 1 March 1992 (1992-03-01), pages 1115 - 1118 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023433A1 (en) * | 2013-08-14 | 2015-02-19 | Primeradx, Inc. | Compositions and methods for multiplex analysis of nras and braf nucleic acids |
| CN105705655A (en) * | 2013-08-14 | 2016-06-22 | 佳根曼斯菲尔德有限公司 | Compositions and methods for multiplex analysis of NRAS and BRAF nucleic acids |
| JP2016527899A (en) * | 2013-08-14 | 2016-09-15 | キアゲン マンスフィールド インコーポレイテッド | Compositions and methods for multiplex analysis of NRAS and BRAF nucleic acids |
| EP3150719A4 (en) * | 2014-05-30 | 2018-01-03 | Jiaxing ACCBDiagnostics Ltd. | Nras gene mutation detection kit |
| CN104372103A (en) * | 2014-12-05 | 2015-02-25 | 武汉友芝友医疗科技有限公司 | NRAS gene mutation detection kit |
| CN105986018A (en) * | 2015-02-06 | 2016-10-05 | 上海赛安生物医药科技有限公司 | NRAS gene mutation detection system and kit thereof |
| KR20170009605A (en) * | 2015-07-17 | 2017-01-25 | 서울대학교산학협력단 | Composition for detecting mutations of NRAS gene and kit comprising the same |
| KR102600347B1 (en) | 2015-07-17 | 2023-11-09 | 주식회사 젠큐릭스 | Composition for detecting mutations of NRAS gene and kit comprising the same |
| TWI586810B (en) * | 2016-07-18 | 2017-06-11 | 豐技生物科技股份有限公司 | Method for detecting mutation sites of nras gene |
| CN107937525A (en) * | 2017-12-08 | 2018-04-20 | 益善生物技术股份有限公司 | NRAS mutation detection kits and extension primer based on Luminex |
| CN107937525B (en) * | 2017-12-08 | 2020-10-30 | 益善生物技术股份有限公司 | NRAS mutation detection kit and extension primer based on liquid chip method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102994619B (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102994619B (en) | NRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN102994617B (en) | HRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN102994621B (en) | PTPN11 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031369B (en) | CDKN2A gene mutation detection specific primer and liquid chip | |
| CN103031370A (en) | RB1 gene mutation detection specific primer and liquid chip | |
| CN103031365B (en) | ATM gene mutation detection specific primer and liquid chip | |
| CN102994622B (en) | MET gene mutation detection specificity primer and liquid chip thereof | |
| CN103031364B (en) | FGFR3 gene mutation detection specific primer and liquid chip | |
| CN103031367A (en) | VHL (Von Hippel Lindau) genetic mutation detection specific primer and liquid phase chip | |
| CN103031368B (en) | FGFR1 gene mutation detection specific primer and liquid chip | |
| CN102994623B (en) | STK11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102191337A (en) | Specific primers and liquid phase chip for detecting polymorphism of cyckin-dependent kinase 5 regulatorysubunit-associated protein 1-like 1(CDKAL1) gene | |
| CN102994620B (en) | AKT1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102912002A (en) | ABCB2 gene polymorphism detection specific primers and liquid chip | |
| CN102994625B (en) | PIK3R1 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031366B (en) | FGFR2 gene mutation detection specific primer and liquid chip | |
| CN102191335B (en) | Specific primer and liquid-phase chip for SNP (single nucleotide polymorphism) detection of PIGU (phosphatidylinositol glycan anchor biosynthesis, class U) genes | |
| CN103031371B (en) | CDH1 gene mutation detection specific primer and liquid chip | |
| CN102994616B (en) | MEK1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102304565B (en) | Specific primers and liquid phase chip for polymorphic detection of hemochromatosis (HFE) gene | |
| CN103451273B (en) | TGM5 gene mutation detection specific primer and liquid phase chip | |
| CN103374608A (en) | MTRR (5-methyltetrahydrofolate-homocysteine methyltransferase reductase) gene mutation detection specific primers and liquid chip | |
| CN102952870A (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A2 gene | |
| CN102994624A (en) | PIK3R5 gene mutation detection specificity primer and liquid chip thereof | |
| CN102912003A (en) | ABCB1 gene polymorphism detection specific primers and liquid chip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant after: Surexam Biological Technology Co., Ltd. Address before: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant before: Guangzhou Yishan Biotechnology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU YISHAN BIOTECHNOLOGY CO., LTD. TO: SUREXAM BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |